Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice

T. Lazard, C. Perronne, Y. Cohen, J. Grosset, J. L. Vilde, J. J. Pocidalo

Research output: Contribution to journalArticle

Abstract

We compared the activities of two different biological-response modifiers with that of clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. Mice were pretreated daily with clarithromycin (50 mg/kg of body weight subcutaneously [s.c.]), RU-40555 (100 mg/kg s.c.), or granulocyte colony-stimulating factor (G-CSF) at low dose (15 μg/kg intraperitoneally [i.p.]) or high dose (300 μg/kg i.p.) 3 days before intravenous challenge with 2.5 x 107 CFU of the MO-1 strain of M. avium complex. Mice were treated daily until sacrifice at day 1, 8, 15, or 21 after challenge, and the numbers of CFU were measured per gram of tissue in lung and spleen. Compared at day 21 with control treatment, clarithromycin significantly decreased the level of infection in spleen (P <0.0001) and lungs (P <0.0001). Compared with control treatment, G-CSF at low dose had no activity, but G-CSF in combination with clarithromycin was more effective than clarithromycin alone in spleen (P <0.05) and lungs (P <0.015). The high dose of G-CSF was as effective as the low dose. RU-40555 alone had no beneficial activity. The RU- 40555-clarithromycin combination was more effective than control treatment in spleen (P = 0.0001) and lungs (P <0.0005) and more effective than clarithromycin alone in spleen (P <0.009) but not in lungs. Thus, our experiments suggest that clarithromycin alone or in combination with G-CSF should be further evaluated for the prophylaxis of M. avium complex infection.

Original languageEnglish (US)
Pages (from-to)692-695
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume37
Issue number4
StatePublished - 1993
Externally publishedYes

Fingerprint

Mycobacterium avium Complex
Clarithromycin
Granulocyte Colony-Stimulating Factor
Inbred C57BL Mouse
Infection
Spleen
Lung
RU 40555
Immunologic Factors
Body Weight

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. / Lazard, T.; Perronne, C.; Cohen, Y.; Grosset, J.; Vilde, J. L.; Pocidalo, J. J.

In: Antimicrobial Agents and Chemotherapy, Vol. 37, No. 4, 1993, p. 692-695.

Research output: Contribution to journalArticle

@article{ff8c0886984940139faaa59f8e761272,
title = "Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice",
abstract = "We compared the activities of two different biological-response modifiers with that of clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. Mice were pretreated daily with clarithromycin (50 mg/kg of body weight subcutaneously [s.c.]), RU-40555 (100 mg/kg s.c.), or granulocyte colony-stimulating factor (G-CSF) at low dose (15 μg/kg intraperitoneally [i.p.]) or high dose (300 μg/kg i.p.) 3 days before intravenous challenge with 2.5 x 107 CFU of the MO-1 strain of M. avium complex. Mice were treated daily until sacrifice at day 1, 8, 15, or 21 after challenge, and the numbers of CFU were measured per gram of tissue in lung and spleen. Compared at day 21 with control treatment, clarithromycin significantly decreased the level of infection in spleen (P <0.0001) and lungs (P <0.0001). Compared with control treatment, G-CSF at low dose had no activity, but G-CSF in combination with clarithromycin was more effective than clarithromycin alone in spleen (P <0.05) and lungs (P <0.015). The high dose of G-CSF was as effective as the low dose. RU-40555 alone had no beneficial activity. The RU- 40555-clarithromycin combination was more effective than control treatment in spleen (P = 0.0001) and lungs (P <0.0005) and more effective than clarithromycin alone in spleen (P <0.009) but not in lungs. Thus, our experiments suggest that clarithromycin alone or in combination with G-CSF should be further evaluated for the prophylaxis of M. avium complex infection.",
author = "T. Lazard and C. Perronne and Y. Cohen and J. Grosset and Vilde, {J. L.} and Pocidalo, {J. J.}",
year = "1993",
language = "English (US)",
volume = "37",
pages = "692--695",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice

AU - Lazard, T.

AU - Perronne, C.

AU - Cohen, Y.

AU - Grosset, J.

AU - Vilde, J. L.

AU - Pocidalo, J. J.

PY - 1993

Y1 - 1993

N2 - We compared the activities of two different biological-response modifiers with that of clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. Mice were pretreated daily with clarithromycin (50 mg/kg of body weight subcutaneously [s.c.]), RU-40555 (100 mg/kg s.c.), or granulocyte colony-stimulating factor (G-CSF) at low dose (15 μg/kg intraperitoneally [i.p.]) or high dose (300 μg/kg i.p.) 3 days before intravenous challenge with 2.5 x 107 CFU of the MO-1 strain of M. avium complex. Mice were treated daily until sacrifice at day 1, 8, 15, or 21 after challenge, and the numbers of CFU were measured per gram of tissue in lung and spleen. Compared at day 21 with control treatment, clarithromycin significantly decreased the level of infection in spleen (P <0.0001) and lungs (P <0.0001). Compared with control treatment, G-CSF at low dose had no activity, but G-CSF in combination with clarithromycin was more effective than clarithromycin alone in spleen (P <0.05) and lungs (P <0.015). The high dose of G-CSF was as effective as the low dose. RU-40555 alone had no beneficial activity. The RU- 40555-clarithromycin combination was more effective than control treatment in spleen (P = 0.0001) and lungs (P <0.0005) and more effective than clarithromycin alone in spleen (P <0.009) but not in lungs. Thus, our experiments suggest that clarithromycin alone or in combination with G-CSF should be further evaluated for the prophylaxis of M. avium complex infection.

AB - We compared the activities of two different biological-response modifiers with that of clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. Mice were pretreated daily with clarithromycin (50 mg/kg of body weight subcutaneously [s.c.]), RU-40555 (100 mg/kg s.c.), or granulocyte colony-stimulating factor (G-CSF) at low dose (15 μg/kg intraperitoneally [i.p.]) or high dose (300 μg/kg i.p.) 3 days before intravenous challenge with 2.5 x 107 CFU of the MO-1 strain of M. avium complex. Mice were treated daily until sacrifice at day 1, 8, 15, or 21 after challenge, and the numbers of CFU were measured per gram of tissue in lung and spleen. Compared at day 21 with control treatment, clarithromycin significantly decreased the level of infection in spleen (P <0.0001) and lungs (P <0.0001). Compared with control treatment, G-CSF at low dose had no activity, but G-CSF in combination with clarithromycin was more effective than clarithromycin alone in spleen (P <0.05) and lungs (P <0.015). The high dose of G-CSF was as effective as the low dose. RU-40555 alone had no beneficial activity. The RU- 40555-clarithromycin combination was more effective than control treatment in spleen (P = 0.0001) and lungs (P <0.0005) and more effective than clarithromycin alone in spleen (P <0.009) but not in lungs. Thus, our experiments suggest that clarithromycin alone or in combination with G-CSF should be further evaluated for the prophylaxis of M. avium complex infection.

UR - http://www.scopus.com/inward/record.url?scp=0027499428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027499428&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 692

EP - 695

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -